MK 1642Alternative Names: MK-1642
Latest Information Update: 21 Dec 2007
At a glance
- Originator Merck & Co
- Class Antihyperglycaemics
- Mechanism of Action Undefined mechanism
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Type 2 diabetes mellitus
Most Recent Events
- 03 Apr 2007 Phase-I clinical trials in Type-2 diabetes mellitus in USA (unspecified route)